Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants
1998

Linomide Blocks Angiogenesis in Breast Cancer

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): M Ziche, S Donnini, L Morbidelli, A Parenti, G Gasparini, F Ledda

Primary Institution: Department of Pharmacology, University of Florence

Hypothesis

Can linomide effectively block angiogenesis induced by breast carcinoma cells?

Conclusion

Linomide can efficiently and persistently block VEGF-dependent angiogenesis in vivo in the absence of a growing tumor mass.

Supporting Evidence

  • Linomide treatment blocked angiogenesis within 48 hours.
  • The antiangiogenic effect lasted over 10 days after treatment suspension.
  • Linomide did not show cytotoxic effects on resting capillary endothelial cells.

Takeaway

Linomide is a drug that helps stop the growth of new blood vessels in breast cancer, which can help prevent the cancer from spreading.

Methodology

The study used a rabbit cornea model to assess the effect of linomide on angiogenesis induced by breast carcinoma cells.

Limitations

The study was conducted in a rabbit model, which may not fully replicate human responses.

Participant Demographics

Female New Zealand white rabbits (2.5-3 kg) were used in the study.

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication